More than 5,000 research abstracts were presented or published at ASCO by pharmaceutical giants, biotech companies, ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...